DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/2d78f9/autoimmune) has announced the addition of the "Autoimmune Partnering Terms and Agreements" report to their offering.
The Autoimmune Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the autoimmune partnering deals and agreements entered into by the worlds leading healthcare companies.
The report provides a detailed understanding and analysis of how and why companies enter autoimmune partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors autoimmune technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not.
In addition, a comprehensive appendix is provided with each report of all autoimmune partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in autoimmune partnering and dealmaking since 2010.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of autoimmune technologies and products.
Autoimmune Partnering Terms and Agreements includes:
- Trends in autoimmune dealmaking in the biopharma industry since 2010
- Analysis of autoimmune deal structure
- Access to headline, upfront, milestone and royalty data
- Case studies of real-life oncology deals
- Access to over 700 autoimmune deals since 2010 and contract documents where available
- The leading autoimmune deals by value since 2010
- Most active autoimmune dealmakers since 2010
- The leading autoimmune partnering resources
In Autoimmune Partnering Terms and Agreements, the available contracts are listed by:
- Headline value
- Upfront payment value
- Royalty rate value
- Stage of development at signing
- Deal component type
- Technology type
- Specific autoimmune therapy indication
For more information visit http://www.researchandmarkets.com/research/2d78f9/autoimmune